Search results for "Prostate Cancer"

Results 21 - 30 of about 109 for "Prostate Cancer".

Men's health

Estimates suggest that needle biopsy would diagnose 32% of them with prostate cancer. ... Many contemporary men receiving treatment for localized prostate cancer are unlikely to benefit from the intervention,” the authors wrote.
August 2010

Leflunomide gets boxed warning, ARBs under review

Cabazitaxel (Jevtana), a chemotherapy drug used with prednisone for prostate cancer. ... It is the first treatment for advanced, hormone-refractory prostate cancer that has worsened during or after treatment with docetaxel.
September 2010


found. Decision aids improved participants' informed decision making about prostate cancer screening but did not change the actual screening rates, a study found. ... one month and 13 months for prostate cancer knowledge, decisional conflict, decisional
August 2013


Prostate cancer mortality varied according to disease risk but not by number of comorbid conditions. ... 3.3), respectively, in the subhazard of prostate cancer mortality compared with those treated aggressively.
May 2013

Prostate cancer

Radical prostatectomy was associated with fewer deaths from prostate cancer compared to watchful waiting, a Scandinavian study found. ... Two large, randomized, controlled trials are under way to determine whether treatment will reduce mortality in men
May 2011

Heparin labeling changed, non-egg flu vaccine approved

An expanded approval of abiraterone acetate (Zytiga) to treat metastatic castration-resistant prostate cancer prior to chemotherapy. ... The drug was initially approved in November 2011 for use in patients whose prostate cancer progressed after treatment
February 2013

Prostate cancer

The primary outcome of this study was prostate cancer mortality at a median of 10 years of follow-up. ... An accompanying editorial for both studies stated that active monitoring, as compared with treatment of early prostate cancer, leads to increased
September 2016

Recalls expanded on defibrillators, infusion pumps

Sipuleucel-T (Provenge), autologous cellular immunotherapy approved to treat asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment. ... cancer. Most of the studies
July 2010

Prostate cancer

31, 2015. The study's primary outcomes were prostate cancer-specific mortality and mortality from other causes. ... Hazard ratios for prostate cancer mortality did not appear to vary substantially by clinical stage or primary therapy.
March 2019

Cancer screening

In addition, screening programs may prevent approximately three cases of metastatic prostate cancer per 1,000 men screened. ... While PSA is an imperfect tumor marker, it is currently the most widely offered and studied prostate cancer screening test.
May 2018

Prev   1   2   3   4   5   6   7   8   9   10   Next